4-(3H)-quinazolinones N-3 substituted with a five membered heterocycle: A promising scaffold towards bioactive molecules

Identification of Unique Quinazolone Thiazoles as Novel Structural Scaffolds for Potential Gram-Negative Bacterial Conquerors

“…Quinazolone with a fused heterocycle constitutes a paramount functional scaffold bestowing with extensive biological interventions, , which indirectly provokes the exploitation and elucidation of various derivatives by extracting and purifying from natural sources or artificially constructing novel structural molecules. − So far, tremendous quinazolones have been recognized as potential candidates for prescription, and even some achieve remarkable successes in clinical evaluations such as idelalisib, metolazone, and afloqualone. , More importantly, some previous literature studies revealed that quinazolone derivatives possessed favorable performance and satisfactory pharmacokinetics in combating resistant microorganisms. Their structures were generally characterized by the installation of conjugated hydrophobic groups like phenyl derivatives or azoles at the 3-position of quinazolone. − Accordingly, engineering novel quinazolone with hydrophobicity or azoles at the 3-position may represent an effective therapeutic strategy for addressing the dreadful drug-resistant strains.…”

Expedient Discovery for Novel Antifungal Leads Inhibiting Fusarium graminearum: 3-(Phenylamino)quinazolin-4(3H)-ones Deriving from Systematic Optimizations on a Tryptanthrin Structure

“…The structural renovation of natural products could provide multitudinous bioactive leads that have laid the substantial groundwork for the discovery of pharmacologically active molecules . These leads derived from natural products tend to display some irreplaceable advantages over traditional synthetic molecules, such as unparalleled structures, inimitable action mechanisms, and desirable environmental compatibilities. − Widely existing in more than 200 natural alkaloids, quinazolin-4­(3 H )-one has been identified as the nitrogenous skeleton that demonstrates remarkably developing values in medicinal and agricultural chemistries. − As a well-known secondary metabolite bearing a quinazolin-4­(3 H )-one framework, febrifugine was identified as the primary material basis for showcasing the antimalarial activity of Dichroa febrifuga and utilized as a valuable pharmaceutical lead for developing the first quinazolin-4­(3 H )-one medicine named halofuginone . The emergence of this antimalarial agent has inspired the application studies of quinazolin-4­(3 H )-one alkaloids, which has successively generated aqualone (sedative), diproqualone (analgesic), albaconazole (medicinal fungicide), nolatrexed (anticarcinogen), and fluquinconzole (agricultual fungicide) .…”

“…14−16 As a well-known secondary metabolite bearing a quinazolin-4(3H)-one framework, febrifugine was identified as the primary material basis for showcasing the antimalarial activity of Dichroa febrifuga and utilized as a valuable pharmaceutical lead for developing the first quinazolin-4(3H)-one medicine named halofuginone. 17 The emergence of this antimalarial agent has inspired the application studies of quinazolin-4(3H)-one alkaloids, which has successively generated aqualone (sedative), diproqualone (analgesic), albaconazole (medicinal fungicide), nolatrexed (anticarcinogen), and fluquinconzole (agricultual fungicide). 18 In addition, the feasibility of quinazolin-4(3H)-one alkaloids as potential antifungal leads was commendably verified by our previous work that formed antifungal quinazolin-4(3H)-ones bearing a hydrazide or 1,3,4-oxadiazole fragment.…”

Multicomponent synthesis of novel β-carboline-fused imidazolium derivatives via the Mannich reaction: cytotoxicity, molecular docking, and mechanistic studies as angiogenesis inhibitors

“…[6][7][8][9] Fused-nitrogen heterocycles occur widely in natural products and biologically active molecules; they are important building blocks in both materials chemistry and the pharmaceutical industry. [10][11][12][13] In particular, the imidazo [1,5-a]pyridines are a class of aza-fused heterocyclic skeletons that are found in many pharmacologically important compounds. [14][15][16] For example, eFT508 (tomivosertib) is an imidazo [1,5-a]pyridine-based inhibitor of MNK kinases; it has exhibited significant anticancer efficacy in different diffuse large B-cell lymphoma (DLBCL) xenograft models 17 and is now in phase 2 clinical trials (NCT02937675, NCT02605083, and NCT03258398).…”